Prescribing Buprenorphine: Adapting to New Realities
The opioid epidemic continues to be a major public health crisis, driven largely by fentanyl and other synthetic opioids. Buprenorphine is a partial opioid agonist that binds to opioid receptors in the brain. Its unique pharmacological profile, characterized by a ceiling effect, limits the risk of overdose and makes it a safer alternative to full agonists like methadone.
Newer formulations and updated initiation strategies can help stabilize patients and support long-term recovery. The session can be helpful to all clinicians who care for individuals with opioid use. Clinicians can educate and reassure their patients on these updates and guide them to treatment.
LEARNING OBJECTIVES
• Describe the current opioid epidemic landscape
• Assess buprenorphine pharmacology
• Describe unique challenges in buprenorphine initiation
• Define clinical practice and micro (low dose) and macro (high dose) initiation
For trainings that indicate Continuing Education Units (CEUs) are available, contact the organizer and/or the Vermont Office of Professional Regulation to verify that the credits will count toward the continuing education requirements of your licensure or certification.
Virtual
Event Details